Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

doi:10.12998/wjcc.v12.i18.3360

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (309)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

HTML

211

Figures (1-2)

Tables (1-4)

Sum=283

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=15

Jun 26, 2024 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jun 26, 2024; 12(18): 3360-3367
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3360

Table 1 Baseline information

Classification	Research group (n = 60)	Control group (n = 57)	χ²/t	P value
Age (yr)	58.53 ± 7.49	56.84 ± 5.55	1.381	0.170
Sex (male/female)	40/20	34/23	0.619	0.431
Disease course (yr)	2.43 ± 1.01	2.23 ± 0.82	1.172	0.244
Pathological stage (IIIa/IIIb)	35/25	40/17	1.781	0.182
Differentiation degree (low/moderate or high)	21/39	22/35	0.163	0.687
Tumor diameter (cm)	3.71 ± 0.69	3.47 ± 0.79	1.753	0.082

Table 2 Effect of cetuximab + FOLFOX4 regimen on the clinical response of advanced gastric carcinoma patients receiving evidence-based care, n (%)

Classification	Research group (n = 60)	Control group (n = 57)	χ²	P value
CR	12 (20.00)	2 (3.51)
PR	39 (65.00)	27 (47.37)
SD	5 (8.33)	17 (29.82)
PD	4 (6.67)	11 (19.30)
RR	51 (85.00)	29 (50.88)	15.740	< 0.001
DCR	56 (93.33)	46 (80.70)	4.173	0.041

FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; RR: Response rate; DCR: Disease control rate.

Table 3 Effect of cetuximab + FOLFOX4 regimen on safety in advanced gastric carcinoma patients receiving evidence-based care, n (%)

Classification	Research group (n = 60)	Control group (n = 57)	χ²	P value
Liver and kidney dysfunction	0 (0.00)	0 (0.00)
Leukopenia	1 (1.67)	1 (1.75)
Thrombocytopenia	1 (1.67)	2 (3.51)
Rash	3 (5.00)	3 (5.26)
Diarrhea	1 (1.67)	2 (3.51)
Total	6 (10.00)	8 (14.04)	0.452	0.502

FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil.

Table 4 Influence of the cetuximab + FOLFOX4 regimen on the improvement in quality of life in advanced gastric carcinoma patients receiving evidence-based care, n (%)

Classification	Research group (n = 60)	Control group (n = 57)	χ²	P value
Enhancement	43 (71.67)	30 (52.63)	4.514	0.034
Stability	15 (25.00)	23 (40.35)	3.141	0.076
Decline	2 (3.33)	4 (7.02)	0.816	0.367

FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil.

Citation: Ying H, Huang RJ, Jing XM, Li Y, Tong QQ. Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care. World J Clin Cases 2024; 12(18): 3360-3367
URL: https://www.wjgnet.com/2307-8960/full/v12/i18/3360.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i18.3360